PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

Under the Paperwork Reduction Act of 199

persons are required

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to respond to a collection of information unless it contains a valid OMB control number

Substitute for	titute for Form 1449/PTO		Complete if Known		
			Application Number	10/790,544	
INFO	RMATION	N DISCLOSURE	Filing Date	March 1, 2004	
			First Named Inventor	Miroslav Colic	
STATEMENT BY APPLICANT (Use as many sheets as necessary)			Art Unit	1646	
		_	Examiner Name	Xiaozhen Xie	
Sheet	1 01	2	Attorney Docket Number	4904-4DIV	

			U.S. PATI	ENT DOCUMENTS		
Examiner Cite Initials* No.		Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant	
Initiais*	No.	Number-Kind-Code ² (if	MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-		19		
		US-				
		US-				
		US-				
		US-				
	-	US-				
		US-				

			FOREIGN P	ATENT DOCUMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³⁻ Number ⁴⁻ Kind-Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Te

	T		
Examiner Signature		Date Considered	

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/PTO					Co	mplete if Known
					Application Number	10/790,544
INFO	DMATIO	N DI	SCI O	CHIDE	Filing Date	March 1, 2004
	INFORMATION DISCLOSURE				First Named Inventor	Miroslav Colic
STATEMENT BY APPLICANT (Use as many sheets as necessary)			JANI	Art Unit	1646	
	(Ose as many s		iecessary)		Examiner Name	Xiaozhen Xie
Sheet	2	of	2		Attorney Docket Number	4904-4DIV

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Katic, M., et al., A Clinoptilolite Effect on Cell Media and the Consequent	
	:	Effects on Tumor Cells in vitro, Frontiers in Bioscience 11, p. 1722-1732 (2006).	
		Žarković, N., et al., Anticancer and Antioxidative Effects of Micronized	
		Zeolite Clinoptilolite, Anticancer Res. 2003 Mar-Apr; 23(2B): 1589-95.	
		Martin-Kleiner, I., et al., The Effect of the Zeolite Clinoptilolite on Serum Chemistry and Hematopoiesis in Mice, <i>Food and Chemical Toxicology</i> 39 (2001) p. 717-727.	
		Pavelić, K., et al., Natural Zeolite Clinoptilolite: New Adjuvant in	
		Anticancer Therapy, J. Mol. Med. (2001) 78:708-720.	
		Pavelić, K., et al., Immunostimulatory Effect of Natural Clinoptilolite as a Possible Mechanism of its Antimetastatic Ability, <i>J. Cancer Res. Clin. Oncol.</i> (2002) 128:37-44.	
# ***			

Examiner	Date
Signature	
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.